Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 11, 2013
Orisett is a naturally derived, patent-pending nutraceutical that defines the glucose management category. The product contains low molecular weight chitosan oligosaccharide bioactives derived from crab shells. According to NutraGenesis, it is clinically proven to help promote both long-term blood sugar maintenance as well as short-term post-prandial responses through multiple mechanisms of action.
Orisett was developed and manufactured by NutraGenesis' supply partner Kunpoong Bio Co. of South Korea, an international supplier of chitosan oiligosaccharides.
Orisetts efficacy and safety have been demonstrated in short-term and long-term randomized, double-blind, placebo-controlled human clinical trials involving healthy subjects and pre-clinical research.
We are very excited about the launch of Orisett into the North American marketplace and the vast potential for this state-of-the-art ingredient," said NutraGenesis president Suzanne McNeary. With the glucose management category predicted to grow to $240 million by 2019, clinically proven Orisett has the potential to gain significant market share."
Orisett may be utilized as either a stand-alone ingredient or as the featured proprietary ingredient in glucose maintenance and metabolic wellness dietary supplements formulations. Orisett can formulated for a variety of applications, including capsules, tablets, nutrition bars, stick packs, drink mixes and gummies.
You May Also Like
Tianeptine sales spur another FDA warning, action by state lawmakersFeb 20, 2024
Formulating the future: The industry may not be ready for AI in product development, and AI might not be ready for the industry, eitherFeb 20, 2024
Beyond the primary outcome: How exploratory analysis can deliver unexpected new insightsFeb 19, 2024
Survey shows dietitians concerned about TikTok misinformationFeb 16, 2024